Modern management for brain metastasis patients using stereotactic radiosurgery: literature review and the authors’ gamma knife treatment experiences

Abstract: Historically, whole brain radiotherapy was administered to most patients with brain metastases. However, over the past three decades, stereotactic radiosurgery (SRS), targeted at individual cranial lesions, has been accepted widely. In this study, based on the authors’ experiences along with published data, recent trends in SRS for brain metastases are discussed. This article focuses on the following issues: 1) How many tumors can or should be treated with SRS? 2) Two-/three-staged SRS for relatively large tumors, 3) post- or preoperative SRS, and 4) repeat SRS.

Keywords: brain metastases, radiotherapy, radiosurgery, gamma knife

Introduction

The late Professor Lars Leksell launched the use of gamma knife radiosurgery (GKRS) for patients with functional neurosurgical disorders, for example, Parkinson’s disease and intractable pain, in 1968.1 Within a few years, he and his colleagues had begun using GKRS to treat patients with cerebral arteriovenous malformations as well as certain benign primary brain tumors, namely, craniopharyngiomas, meningiomas, vestibular schwannomas, and pituitary adenomas.2 After two decades, GKRS was successfully applied to treat brain metastasis (BM) from a recurrent hypernephroma, as first reported by Lindquist.3 Stereotactic radiosurgery (SRS) has since been applied as a primary or boost, with whole brain radiotherapy (WBRT), treatment for growing numbers of BM patients. Many tumors, regardless of whether they are radiosensitive or resistant, single or multiple, can be adequately managed with SRS. This technique is particularly suitable for metastatic lesions because most are well-circumscribed. Therefore, the last decade of the 20th century witnessed a remarkable expansion of SRS, now being used worldwide, as well as various innovations in linac-based systems, that is, Cyber Knife, Synergy, Novalis, Tomotherapy, and so on. Very recently, Kann et al4 reported, based on their series of 75,953 BM patients identified in the National Cancer Database during the 2009 through 2014 period, that the overall utilization rate for SRS rose from 9.8% in 2004 to 25.6% in 2014 (p<0.001), with an average increase of 1.6% annually. The annual increase in SRS application was higher from 2009 to 2014 than from 2004 to 2009 (2.6% vs 0.5% per year, respectively).4

The authors’ personal experiences in using only a gamma knife, as summarized in Tables 1 and 2, are reviewed along with relevant recently-published data. Herein, we...
focus on current trends in SRS for BMs, especially recently-developed applications, ie, larger BM numbers, larger BM volumes, adjuvant treatment involving surgical removal and repeat SRS. These issues have yet to be fully explored and remain controversial.

What are the generally accepted concepts?

Numerous publications have focused on radiosurgery for BMs. The authors do not intend to review them comprehensively in this study. Such a review is beyond the scope of this article, but the authors’ personal experiences with 3498 patients (5055 procedures, as of the end of 2017) who have undergone GKRS for BMs since 1998 (Table 1), are summarized in this study along with much of what we have learned from only one prospective observational study (JLGK0901).5,6

1. Although the limitation of treatable lesion size is crucial for selecting SRS, tumor control rates of 90%, or even slightly better, can be obtained if one to four lesions which were initially diagnosed and sufficiently small are irradiated with a peripheral dose of at least 20 Gy. In such cases, true recurrence is exceedingly rare.

2. The crude SRS-related complication incidence, that is, that of symptomatic radionecrosis of the normal brain, is generally below 3.0% in cohorts including patients with relatively short survival. Not unexpectedly, however, the crude complication incidence exceeds 5%, or even 10%, in a rather special group of patients surviving for 3–5 years, or even longer, after SRS.

3. Longer survival cannot be expected because the survival duration depends primarily on the status of non-brain lesions (including the primary tumor). Most patients, 80%–90%, die of causes other than brain tumor progression. Thus, the majority can maintain good brain function until death.

4. Factors known to predict longer survival are younger age, female gender, better performance status, absence of neurological symptoms, solitary tumor, controlled primary tumor, and absence of active non-BMs.

5. Controversy persists as to whether radiosurgery should be combined with WBRT. A randomized study found the only benefit of combining radiosurgery with WBRT

<table>
<thead>
<tr>
<th>Table 1 Clinical characteristics before gamma knife radiosurgery</th>
<th>Table 2 Radiosurgical parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Characteristic</strong></td>
<td><strong>No. of patients (%)</strong></td>
</tr>
<tr>
<td>No. of patients</td>
<td>3498</td>
</tr>
<tr>
<td>Age Median 66 years</td>
<td>Range 19–96 years</td>
</tr>
<tr>
<td>&lt;65 years 1554 (44.4)</td>
<td>≥65 years 1944 (55.6)</td>
</tr>
<tr>
<td>Sex Male 2091 (59.8)</td>
<td>Female 1407 (40.2)</td>
</tr>
<tr>
<td>Neurological symptoms Yes 1832 (52.4)</td>
<td>No 1666 (47.6)</td>
</tr>
<tr>
<td>KPS score ≥80% 2701 (77.2)</td>
<td>&lt;70% 797 (22.8)</td>
</tr>
<tr>
<td>Modified RPA class1+2a 700 (22.5)</td>
<td>2b 1072 (30.6)</td>
</tr>
<tr>
<td>2c+3 1636 (46.8)</td>
<td>Primary cancer Non-small cell lung cancer 1941 (55.5)</td>
</tr>
<tr>
<td>Primary cancer status Controlled 1208 (34.4)</td>
<td>Small cell lung cancer 340 (9.7)</td>
</tr>
<tr>
<td>Uncontrolled 2293 (65.6)</td>
<td>Breast cancer 399 (11.4)</td>
</tr>
<tr>
<td>Presentation Synchronous 664 (19.0)</td>
<td>Gastrointestinal tract 392 (11.2)</td>
</tr>
<tr>
<td>Metachronous 2832 (81.0)</td>
<td>Kidney 137 (3.9)</td>
</tr>
<tr>
<td>Extracranial metastases Yes 1771 (50.6)</td>
<td>Others 289 (8.3)</td>
</tr>
<tr>
<td>No 1727 (49.4)</td>
<td>Primary cancer status Controlled 1208 (34.4)</td>
</tr>
<tr>
<td>Prior surgery Yes 643 (18.4)</td>
<td>Uncontrolled 2293 (65.6)</td>
</tr>
<tr>
<td>No 2855 (18.4)</td>
<td>Presentation Synchronous 664 (19.0)</td>
</tr>
<tr>
<td>Prior WBRT Yes 181 (5.2)</td>
<td>Extracranial metastases Yes 1771 (50.6)</td>
</tr>
<tr>
<td>No 3317 (94.8)</td>
<td>Primary cancer status Controlled 1208 (34.4)</td>
</tr>
</tbody>
</table>

Notes: *Values are presented as the number of patients (%) unless otherwise indicated. †Refer to the studies Yamamoto et al.72,73

Abbreviations: KPS, Karnofsky performance score; RPA, recursive partitioning analysis; WBRT, whole brain radiotherapy.
to be that re-treatment, necessitated by new lesions, is significantly reduced. Neither the survival rate nor the local tumor recurrence rate differed significantly between the groups with versus without WBRT. However, post-WBRT decline of neurocognitive function was described as being clinically meaningful. Very recently, Brown et al stated that, based on their randomized study (Alliance), SRS alone may be a preferred strategy for patients with 1–3 BMs because using SRS alone, as compared with SRS+WBRT, was associated with less cognitive deterioration.

**Can patients with larger numbers of BM be treated?**

**SRS for 5–10 BMs**

“How many tumors can and should be treated with SRS?” has long been the major question for specialists in the field of SRS for BMs. Historically, with a linac system, the upper limit is generally considered to be 3–4 tumors in a single session due mainly to the technical difficulties encountered in dose planning and to the time-consuming procedures required. In contrast, as we reported previously, based on our experiences and those of other groups with GKRS since the 1990s, the upper limit for lesion numbers that can be treated in a 1-day session has been 30, or even slightly more, such that the prolonged procedure time again accounts for the limitation in number of tumors. If a patient has more than 40 lesions, the authors recommend that the procedure be divided into two sessions, 1 day apart, with the patient keeping the stereotactic head frame on overnight, or into multiple sessions with intervals of several weeks or months. Also, with a recently developed linac system, more than 10, possibly even more than 20, lesions can be easily irradiated within a day.

Because numerous factors in BM patients impact outcomes, we can no longer rely on a one-size-fits-all treatment paradigm. Still, solid patient selection criteria are necessary for SRS of BMs. Despite a lack of good scientific evidence, WBRT was strongly recommended in most industrialized nations until 2013 while SRS alone for patients with ≥4, or even ≥5, tumors had not as yet become accepted. However, a trend for patients with ≥5, or even ≥10, tumors to be considered for SRS alone was already apparent early in this century. Since Yamamoto et al reported two BM patients with ≥10 tumors who were successfully managed with SRS, retrospective studies of SRS-treated patients with several BMs have been published. Most notably, the authors conducted a case-matched study to reassess whether SRS alone for tumor numbers ≥5 yielded results different from those of treating 1–4 (548 patients in each group). Although the post-SRS overall median survival time (MST) difference, 0.9 months, between the two groups was statistically significant, this difference was not taken to be clinically relevant. The study subjects with tumor numbers ≥5 had non-inferior results, when compared to the other tumor number group, with no major differences being seen in neurological death, local recurrence, repeat SRS required for new tumors, maintenance of good neurological state, and SRS-related complications.

However, the JLGK0901 Study launched a major breakthrough in SRS for BM patients, with the perhaps overly strict criteria of the National Comprehensive Cancer Network Guideline and other guidelines having since been revised. This prospective observational study, including 1194 BM patients, clearly showed the non-inferiority of SRS without WBRT as the initial treatment for those with 5–10 BMs versus patients with 2–4 in terms of overall survival (OS) as well as most secondary end points if the tumor volume did not exceed 10 cc which corresponds to ~2.7 cm in diameter. Considering the present lack of evidence supporting WBRT superiority over SRS alone for patients with 5–10 tumors, their results are considered to constitute the highest level of evidence, to date, which would allow SRS alone to be advocated for such patients.

**SRS for ≥10 tumors**

Next, a need was recognized to reappraise whether the results of SRS alone for patients with ≥10 BMs are inferior to those of patients with fewer metastatic tumors. In 1998, members of our research group presented the first clinical observations, suggesting the feasibility of SRS for patients with multiple lesions. The report described two patients receiving GKRS, one with 37 and the other with 36 intracranial metastatic lesions. Both the patients had lung cancer, and all lesions visualized on magnetic resonance (MR) imaging were irradiated and then confirmed, post-radiosurgically, to have disappeared or undergone marked shrinkage. One of these two patients, who had been symptomatic prior to SRS, showed marked clinical improvement 2 weeks after irradiation. These early experiences, though based only on two patients, who died due to their original tumors 20 and 23 weeks after SRS, respectively, raised the possibility of radiosurgery exerting certain beneficial effects in the end-stage management of carefully selected patients with several intracranial metastases. In other words, maintaining good performance status for a significant portion of a patient’s remaining life might well be possible.
Suzuki et al conducted the first retrospective study on SRS for ≥10 BM. In 2000, they reported, based on 24 patients, that although the post-SRS MST was only 11 weeks with cumulative survival rates of 70.4%, 49.3%, and 12.3% at the 12th, 24th, and 36th post-SRS month, respectively, none of their patients died due to brain disease progression. In 2008, Kim et al described 26 patients receiving GK SRS. According to their retrospectively obtained results, post-SRS MST was 34 weeks, the local control rate 79.5%. Among 18 patients who died, causes of death could not be determined in two, but were confirmed in the other 16 to be non-brain diseases in six and brain diseases in 10. Univariable analyses demonstrated synchronous presentation, higher Karnofsky Performance Score (better than 80%) and controlled primary diseases to be favorable prognostic factors. In 2009, Yamamoto et al, employing a data set of 456 non-lung cancer patients including 82 with ≥10 BMs, described post-SRS results focusing on multiple BMs. One of their major conclusions, from this retrospective study, was that despite tumor number having a significant impact on the duration of survival, ~85% of patients died of causes other than brain disease progression, regardless of the number of tumors.

In 2000, Chang et al studied 323 BM patients who underwent GKRS. Their patients were divided into four groups according to BM numbers: Group 1, 1–5; Group 2, 6–10; Group 3, 11–15; and Group 4, ≥16. According to their analysis, neither survival times nor local tumor control rates differed significantly among the four groups, although the probability of new lesion development in the brain was noted to be greater in Group 4.

In 2012–2014, three studies evaluated the outcomes in patients with ≥10 BM treated with SRS. Rava et al reported, based on 53 patients with ≥10 BMs treated with SRS (mean tumor number: 11) whose post-SRS MSTs exceeded 6 months, that aggressive local treatment is still an option, although rapid central nervous system failure is to be anticipated. Grandhi et al reported, based on 61 patients with ≥10 BMs receiving SRS (mean, 13 tumors), whose post-SRS MST was 4 months, that SRS can be applied safely and effectively for treating intracranial disease with a high local control rate in patients with ≥10 BMs. In those with fewer tumors, a non-melanomatous primary lesion, controlled systemic disease, and a low recursive partitioning analysis (RPA) class, SRS might well be one of the most effective treatments currently available. Their conclusion was that SRS can reasonably be regarded as a first-line treatment. Patients with breast cancer constituted a group of individuals likely to experience major benefit from SRS alone, with both survival and the time until central nervous system recurrence being prolonged. The present authors conducted a case-matched study to reappraise whether treatment outcomes were truly inferior for tumor numbers ≥10 versus 2–9. We compared group A, with 2–9 tumors, to group B harboring ≥10 tumors (467 patients each in groups A and B). No significant difference in post-SRS MSTs (months) was detected between the two groups (7.1/group A vs 6.9/group B, hazard ratio [HR]: 1.238 [95% confidence interval {CI}: 0.835–1.834], p=0.29). Other post-SRS treatment results, that is, neurological death-free survival time and cumulative incidences of local recurrence, the need for repeat SRS to manage new lesions, neurological deterioration, and SRS-related complications, were not inferior in the group B as compared to the group A patients. These observations allowed us to conclude that patients with ≥10 tumors are not unfavorable candidates for SRS alone (Table 3).

Nevertheless, we should keep in mind that survival is determined mainly by systemic disease rather than intracranial status. Although debates continue as to whether >5 intracranial lesions at the time of SRS tend to be associated with more new lesions at the first follow-up MR imaging, thereby warranting additional treatment including WBRT or further SRS in a short interval, extensive intracranial and extracranial disease burdens remain a concern.

**Is SRS for multiple BMs safe?**

In a phantom experiment, the first author and another group of colleagues analyzed cumulative whole brain irradiation doses based on the treatment protocol for a patient with 48 lesions. The estimated cumulative irradiation doses were 2.60–6.69 Gy at sites located some distance from the targets, indicating that whole brain irradiation was not delivered at unacceptably high doses. It is noteworthy that these results are highly consistent with those described in this study. Yang et al, based on their dose–volume histogram analysis using a model with placement of 25 targets within the whole brain followed by irradiation with a maximum dose of 40 Gy, reported that the 50% whole brain dose was no more than 5 Gy. Furthermore, Boone et al reported recently, based on their experiences managing 10 patients with 6–15 BMs treated using a linear accelerator system, that the largest calculated cumulative dose to the entire brain was ~5.0 Gy. In 2002, the first author and another group of colleagues, studying a series of 80 patients with ≥10 BMs (median: 17, maximum: 43) undergoing SRS, estimated that the absorbed doses to the whole brain ranged from 2.16 to 8.51 Gy (median: 4.71 Gy). They
also reported, based on 167 BM patients surviving more than 3 years after SRS (including 11 with ≥10 BMs), that tumor numbers had no impact on the incidence of SRS-related complications (HR: 1.066, 95% CI: 0.968–1.131, p = 0.1567).26 Nevertheless, the safety and efficacy of this approach, using alternative technologies (eg, single isocenter linac techniques) and fractionation schemes (eg, 3–5 fraction schemes), have not yet been confirmed, and further studies are awaited. In fact, Ma et al found that normal brain volumes receiving 4 and 12 Gy were higher with a linac-based SRS platform than with Gamma Knife Perfexion, in patients with 3, 6, 9, and 12 irradiated tumors.27 However, this issue remains controversial.28–30

Two/three-staged treatment and fractionated GKRS for relatively large lesions

In general, it is recommended that a BM with a diameter exceeding 3 cm be surgically excised. However, some patients have contraindications for general anesthesia or refuse highly invasive operative procedures. In such cases, as Higuchi et al noted, three-staged GKRS (3-st-GK-Tx) is useful.31 According to their report describing 43 patients, a 10.0 Gy peripheral dose is delivered in each procedure with a 2-week interval. The overall MST after 3-st-GK-Tx was 8.8 months (95% CI: 6.5–11.1 months), and the actuarial survival rate was 62.5% at the 6th and 26.4% at the 12th post-3-st-GK-Tx month. The treatment results obtained by the present authors with this strategy were, surprisingly, quite similar to those of Higuchi et al’s patient group.32 In our 78 patients who underwent 3-st-GK-Tx, the overall MST after 3-st-GK-Tx was 8.1 (95% CI: 5.6–12.0) months, while the actuarial survival rate was 55.1% at the 6th and 35.2% at the 12th post-3-st-GK-Tx month. The incidences of neurological death, neurological deterioration, salvage SRS for new lesions, local recurrence, and treatment-related complications did not differ significantly between these two groups. Thus, we could reasonably conclude that carefully selected patients with relatively large BMs are favorable candidates for 3-st-GK-Tx.

Because three procedures are regarded as being burdensome for both patients and physicians, two-staged GKRS (2-st-GK-Tx) was proposed by Yomo et al.33,34 Their treatment strategy involved total doses of 20–30 Gy being delivered in two sessions with an interval of 3–4 weeks. Their treatment results and recently reported study results are summarized in Table 4.35–37

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment modalities</th>
<th>No. of patients</th>
<th>No. of tumors, median (mean), maximum (range) (cc)</th>
<th>Cumulative tumor volume mean (range) (cc)</th>
<th>Largest tumor volume mean (range) (cc)</th>
<th>Peripheral dose mean (range) (Gy)</th>
<th>Median survival times (months)</th>
<th>Local recurrence rates (%)</th>
<th>Salvage SRS rates (%)</th>
<th>Complication rates (%)</th>
<th>Neurologic death rates (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yamamoto et al10</td>
<td>GKRS</td>
<td>20</td>
<td>20</td>
<td>15 (2–25)</td>
<td>20</td>
<td>20</td>
<td>3.5, 5.3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Suzuki et al11</td>
<td>GKRS</td>
<td>24 (20–47)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>3.0</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kim et al13</td>
<td>GKRS</td>
<td>26 (17–37)</td>
<td>109 (1.0–42.2)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>7.8</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Chang et al15</td>
<td>GKRS</td>
<td>36 (13–14)</td>
<td>58 (0.1–58.2)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>15 (9–23)</td>
<td>3.0</td>
<td>20.5</td>
<td>13.8</td>
</tr>
<tr>
<td>Rava et al16</td>
<td>GKRS</td>
<td>50 (11–24)</td>
<td>61 (1.1–61.1)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>13 (12–20)</td>
<td>3.0</td>
<td>20.5</td>
<td>13.8</td>
</tr>
<tr>
<td>Grandi et al18</td>
<td>GKRS</td>
<td>360</td>
<td>360</td>
<td>14 (17–69)</td>
<td>5.8 (0.03–13.0)</td>
<td>16 (12–25)</td>
<td>21 (10–25)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Present study</td>
<td>GKRS</td>
<td>720</td>
<td>720</td>
<td>17 (21.9)</td>
<td>5.2 (0.03–12.0)</td>
<td>21 (10–25)</td>
<td>5.9</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Notes: a11 ≥11 tumors; b11–16 tumors; c16 tumors; and d16 tumors.

Abbreviations: NA, not available; GKRS, gamma knife radiosurgery.

Table 3 List of studies regarding GKRS for patients with ≥10 brain metastases.
The next question that specialists in this field needed to tackle was whether 3-st-GK-Tx or 2-st-GK-Tx is a better treatment. Recently, Serizawa et al conducted a multi-institutional retrospective study (JLGK1601, UMIN ID; 000022152) to reappraise which of these two protocols, that is, 3-st-GK-Tx or 2-st-GK-Tx, yielded better results. Their analyses revealed that there were no significant differences in several outcomes between the two strategies.38

Oligo-fractionated SRT using a GK

Oligo-fractionated SRT (3–5 fractions) has been widely applied for managing relatively large BMs. However, formerly, GK was rarely employed for oligo-fractionation because the standard GKRS technique requires a pin-based head frame. For the past few years, the Elekta Extend bite-block palatal vacuum immobilization system has been available. This system facilitates performing oligo-fractionated GK SRT. McTyre et al reported on 34 patients with meningiomas, pituitary adenomas, vestibular schwannomas, hemangiomas, or BMs. Although follow-up was brief, they concluded that fractionated GK SRT using this system was well tolerated in patients receiving treatments for large tumors. However, the Extend system is not yet in widespread use due to its technical complexity.

A few years ago, an innovative gamma unit model, the Leksell Gamma Knife Icon (Elekta, A.B., Stockholm, Sweden), became available. This new model is anticipated to make fractionated GK SRS more accessible because it simplifies immobilization by eliminating either the conventional pin-fixation frame or the Extend bite block, with a mask fixation system being used instead.

Surgical removal and SRS

Postoperative SRS

Historically, combining surgical removal and subsequent WBRT was the gold standard for managing patients with a single, relatively large BM, whether symptomatic or not. This approach was based on the Patchell et al report showing that adjuvant WBRT following total removal of a single brain BM significantly reduced local recurrence and remote tumor development rates as compared with those in patients undergoing surgical resection alone. However, they employed a total WBRT dose of 50.4 Gy/28 fr which is very high and would never be applied today. Thus, Kocher et al conducted a randomized controlled trial designed to compare treatment results between two patient groups, one receiving surgery/SRS plus WBRT with a total dose of 30

Table 4 List of studies regarding two-staged and three-stage gamma knife radiosurgery (GKRS) for patients with large brain metastases

<table>
<thead>
<tr>
<th>First author and year</th>
<th>Treatment modality</th>
<th>Number of patients</th>
<th>Number of tumors, median (mean), maximum</th>
<th>Cumulative tumor volume, median (range) (cc)</th>
<th>Largest tumor volume, median (range) (cc)</th>
<th>Peripheral dose, mean (range) (Gy) /procedure</th>
<th>Number of procedures (interval [week])</th>
<th>Median survival times (months)</th>
<th>Local recurrence rates (%)</th>
<th>Complication rates (%)</th>
<th>Neurologic death rates (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Higuchi et al, 1998</td>
<td>GKRS</td>
<td>31</td>
<td>2 (3), 14</td>
<td>16.2 (10.8–35.5)</td>
<td>16.2 (10.8–35.5)</td>
<td>8.8</td>
<td>3 (2)</td>
<td>13.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yomo et al, 2014</td>
<td>GKRS</td>
<td>34</td>
<td>2, 8</td>
<td>NA</td>
<td>16.4 (10.0–56.1)</td>
<td>10–15</td>
<td>2 (3–4)</td>
<td>11.8</td>
<td>15.0/6 months</td>
<td>5.0</td>
<td>17.0</td>
</tr>
<tr>
<td>Dohmen et al, 2017</td>
<td>GKRS</td>
<td>33</td>
<td>2 (2), 7</td>
<td>11.7 (9.8–40.9)</td>
<td>10–11</td>
<td>2 (4)</td>
<td>60/12/12</td>
<td>12.1</td>
<td>15.0/12</td>
<td>6.1</td>
<td>19.0</td>
</tr>
<tr>
<td>Hasegawa et al, 2017</td>
<td>GKRS</td>
<td>36</td>
<td>2, 8</td>
<td>21.0 (10.0–76.0)</td>
<td>10–13</td>
<td>2 (4)</td>
<td>70/12/12</td>
<td>14.3</td>
<td>13.8</td>
<td>1.9</td>
<td>7.3</td>
</tr>
<tr>
<td>Angelov et al, 2017</td>
<td>GKRS</td>
<td>37</td>
<td>2 (5)</td>
<td>10.5 (2.4–31.3)</td>
<td>10–13</td>
<td>2 (5)</td>
<td>10.8/6/12</td>
<td>14.3</td>
<td>13.8</td>
<td>6.4</td>
<td>11.5</td>
</tr>
<tr>
<td>Present Study</td>
<td>GKRS</td>
<td>82</td>
<td>2 (5), 31</td>
<td>24.7 (10.2–92.8)</td>
<td>10–13</td>
<td>3 (2)</td>
<td>8.1/10/10</td>
<td>14.9</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Gy/10 fr and the other surgery/SRS alone. However, local recurrence and neurological death incidences (27% and 27.8%) were far higher than those obtained by Patchell et al (10.2% and 14.4%). In addition, as noted above, WBRT carries the risk of deterioration of neurocognitive function in relatively long surviving patients. As the present authors described in another report, diffuse white matter change, which is suspected to possibly increase the risk of future dementia, was detected by MR imaging in 8%, 50%, 63%, and 84% of patients, respectively, 6, 12, 18, and 24 months after WBRT. Therefore, the current trend favors withholding WBRT until it is necessary, that is, until the development of meningeal or miliary dissemination for which there are no other therapeutic options. Retrospective studies on SRS for postoperative irradiation, reported in the past decade, are summarized in Table 5.

In the authors’ own series of 209 patients who underwent surgical tumor removal plus GK SRS without WBRT, local control failure at the resection site was documented in 10.0%, while 30.6% of these patients developed remote lesions. As presented in Table 5, the MST was 9.8 months, the local recurrence rate 10.0%, and the neurological death rate 19.0%, results very similar to those obtained by Patchell et al. However, the remote recurrence rate (30.6%) in our present study was lower than that in Patchell et al’s observation group (36.9%). It is widely accepted that remote recurrence is more frequent in patients with multiple BMs than in those harboring only a single lesion. Although the results reported by Patchell et al were based entirely on patients with a solitary lesion, 79% of patients in our study had multiple tumors. Furthermore, we consider these differences to reflect the quality of neuroimaging techniques, especially MR imaging, which has advanced remarkably over the past 20 years. The patients in Patchell et al’s study were treated over a 10-year period before 1998, while our patients were all treated in the decade after 1998. With an MR imaging unit capable of higher performance, smaller lesions can be detected much earlier and promptly treated by GK SRS. In fact, the majority of recently published studies have demonstrated higher rates of remote recurrence (maximum of 72.3%) than the 45.6% in Patchell et al’s observation group (Table 5).

### Preoperative SRS

As already mentioned, the relatively high incidence of remote recurrence remains the most serious weakness of postoperative SRS. In particular, cerebrospinal fluid-seeding occurred during follow-up in several patients who had received...
postoperative SRS. Therefore, we previously reported that the incidence of subdural seeding was significantly lower in patients given preoperative GKRS (14.3%/12 months after treatment) than in those receiving postoperative GKRS (61.5%/12 months after treatment, adjusted HR: 9.095, 95% CI: 1.107–74.704, \( p = 0.0339 \)), although neither MST (8.9 months/post-op vs 10.5/pre-op, HR: 1.067, 95% CI: 0.510–2.227, \( p = 0.8638 \)) nor 12th-posttreatment month incidences of new lesions being detected in the brain parenchyma (32.8%/post-op vs 42.1/pre-op, adjusted HR: 1.359, 95% CI: 0.331–5.581, \( p = 0.6703 \)) differed significantly between these two groups.51

Asher et al reported, based on 47 BM patients given SRS followed by surgical removal, respective cumulative survival rates of 77.8% and 60.0% at 6 and 12 months and cumulative local control rates of 97.8%, 85.6%, and 71.8% at 6, 12, and 24 months.56 According to the results of their analyses, only 14.8% of the patients received WBRT. Local failure was more likely with lesions >10 cc \( (p=0.01) \) and >3.4 cm \( (p=0.014) \), with trends being noted for surface lesions \( (p=0.066) \) and eloquent areas \( (p=0.052) \). They concluded that their results demonstrated overall safety and local control equal to, or even better than, those of other published approaches, suggesting the feasibility of this approach as a novel treatment for BM.

### Multiple GK SRS procedures

Although WBRT is generally considered to not be repeatable, SRS has overcome this limitation. Therefore, a growing number of BM patients have recently been treated with SRS twice, three times, or even more. Recent retrospective or prospective studies based on more than 1000 BM patients given SRS alone have demonstrated that re-SRS for new tumors was required in 22%–34% of all cases.57–60 While a number of retrospective studies have documented re-SRS to be safe and effective, all were based on relatively small patient numbers (Table 6).61–66

Koiso et al carried out a retrospective study that was based on a rather large sample size (859 patients) and employed robust statistical methods, that is, competing risk analyses for secondary end points.67 They found that post-2nd SRS MST was 7.4 (95% CI: 7.0–8.2) months. The respective actuarial survival rates were 58.2% and 34.7% at the 6th and 12th post-2nd SRS month. Actuarial neurological death-free survival rates were 94.4% at the 6th and 86.6% at the 12th post-2nd SRS month. The cumulative incidences of local recurrence were 11.2% and 14.9% at the 12th and 24th post-2nd SRS month, respectively.

<table>
<thead>
<tr>
<th>First author and year</th>
<th>Treatment modalities</th>
<th>Number of patients</th>
<th>Number of tumors, median (mean), maximum</th>
<th>New lesions or recurrence</th>
<th>Interval (months) from 1st SRS, median (range)</th>
<th>Largest tumor volume, median [mean] (cc)</th>
<th>Peripheral dose, mean (range) (Gy)</th>
<th>Post-re-SRS median survival times (months)</th>
<th>Local recurrence rates (%)</th>
<th>Futher salvage SRS (%)</th>
<th>Complications rates (%)</th>
<th>Neurologic death rates (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yamanaka et al, 1999</td>
<td>GKRS</td>
<td>41</td>
<td>(3.) (0.1–4.4)</td>
<td>2.4 (1.5–8.9)</td>
<td>6.4 (2.5–41.7)</td>
<td>3.70 (0.01–94.2)</td>
<td>20 (14–22)</td>
<td>7.9 (2.9)</td>
<td>22 (14–28)</td>
<td>9.3%</td>
<td>1.1%</td>
<td>0.1%</td>
</tr>
<tr>
<td>Chen et al, 2000</td>
<td>GKRS</td>
<td>45</td>
<td>(4.) (0.1–10.2)</td>
<td>2.0 (1.5–22.2)</td>
<td>20 (14–22)</td>
<td>9.8 (0.1–20.5)</td>
<td>17.9 (6.0–46.7)</td>
<td>7.9 (2.9)</td>
<td>70% (12 months)</td>
<td>22%</td>
<td>4.2%</td>
<td>11%</td>
</tr>
<tr>
<td>Kwon et al, 2007</td>
<td>GKRS</td>
<td>43</td>
<td>(5.) (1.2–22)</td>
<td>2.2 (1.0–20.5)</td>
<td>15.3 (2.0–52.2)</td>
<td>2.2 (0.1–21.5)</td>
<td>20 (14–22)</td>
<td>7.4 (2.9)</td>
<td>9.3%</td>
<td>11%</td>
<td>0.2%</td>
<td>11%</td>
</tr>
<tr>
<td>Daniel et al, 2013</td>
<td>Linac SRS/SRT</td>
<td>32</td>
<td>mixed</td>
<td>6.0 (3.0–12.1)</td>
<td>20 (14–22)</td>
<td>9 (1–50)</td>
<td>15 (10–20)</td>
<td>17.8 (7.4–46.7)</td>
<td>22 (14–28)</td>
<td>12%</td>
<td>2.2%</td>
<td>11%</td>
</tr>
<tr>
<td>Mckey et al, 2016</td>
<td>GKRS</td>
<td>32</td>
<td>mixed</td>
<td>6.0 (3.0–12.1)</td>
<td>20 (14–22)</td>
<td>9 (1–50)</td>
<td>15 (10–20)</td>
<td>17.8 (7.4–46.7)</td>
<td>22 (14–28)</td>
<td>12%</td>
<td>2.2%</td>
<td>11%</td>
</tr>
<tr>
<td>Koiso et al, 2016</td>
<td>GKRS</td>
<td>859</td>
<td>mixed</td>
<td>6.5 (0.5–74.4)</td>
<td>24 (10–25)</td>
<td>3.70 (0.01–94.2)</td>
<td>20 (14–22)</td>
<td>7.4 (2.9)</td>
<td>14.5%</td>
<td>2.9%</td>
<td>11%</td>
<td>11.5%</td>
</tr>
</tbody>
</table>

Abbreviations: GKRS, gamma knife radiosurgery; SRS, stereotactic radiosurgery; SRT, stereotactic radiotherapy; NA, not available.
respective cumulative incidences of neurological deterioration were 4.5%, 5.8%, 6.7%, 7.2%, and 7.5% at 12, 24, 36, 48, and 60 months after the 2nd SRS. SRS-related complications were documented in 25 patients (2.9%). The cumulative incidences of complications were 1.4%, 2.0%, 2.4%, 3.0%, and 3.0% at 12, 24, 36, 48, and 60 months after the 2nd SRS, respectively. Koiso et al concluded that post-2nd SRS results, not only OS but other secondary end points as well, were not inferior to those after the 1st SRS. Most notably, maintenance of good neurological condition can be anticipated even at the 5th post-2nd SRS year in more than 90% of patients.

Several prognostic grading indexes have been proposed for patients with newly diagnosed BM. However, little is known about prognostic grading indexes for patients receiving salvage treatments, that is, surgery, WBRT, or SRS/ SRT, and so on. We tested, in a data set of 804 re-GKRS patients, the validity of applying five prognostic indexes, RPA, Score Index for Radiosurgery, Basic Score for Brain Metastases, Graded Prognostic Assessment, and Modified RPA. Among these five systems, based on patient number proportions, MST separation among three/four groups, and/or detailed reflection of status changes, the Modified RPA system was concluded to be the most applicable to re-SRS patients. Very recently, a unique grading system, BM velocity (a cumulative number of new brain tumors divided by an interval [years] between the day of the first SRS and the day when follow-up MR imaging showed new BMs), which was specific for post-SRS salvage SRS, was proposed. However, no validity tests using different data sets have been published.

Interpretations
Finally, all specialists working in this field would be well advised to keep in mind the words of Lindquist and Steiner, “Although effective, it must be realized that radiosurgery at best only kills intracranial tumor cells. Suffering should not be prolonged by treatment of terminal patients. Which tumors should be treated? How many tumors can and should be treated?” The gradual diminution of consciousness with the progression of BM, which inevitably occurs, might be Nature’s way of relieving the suffering of terminally ill cancer patients. Recent advances in multidisciplinary management strategies do, however, allow physicians to relieve much of the suffering associated with these end-stage diseases. Furthermore, as physicians, we should always accept the challenge of managing patients with very complex disorders, so long as the patients themselves want to continue active treatment efforts. We should also keep in mind that maintenance of good neurological function and, ultimately, a reduced neurological death incidence, are now recognized as being crucial for managing BM patients.

Disclosure
The authors report no conflicts of interest for this work.

References


Knisely JPS, Yamamoto M, Gross CP. Radiosurgery alone for five or more brain metastases: expert opinion survey. J Neurosurg. 2010;113(Suppl):84–89.


Thomas EM, Popple RA, Markert JM, Fiveash JB. In reply: volumetric arc therapy (RapidArc) vs gamma knife radiosurgery for multiple brain metastases: not only a dosimetric issue. Neurosurgery. 2015;77:E311.


Yamamoto M, Higuchi Y, Serizawa T, et al. Three-Stage Gamma Knife Treatment for Metastatic Brain Tumors Larger than 10 cc: A Two Institute Study including Re-Analyses of Results Published by Higuchi and Colleagues Using Competing Risk Analysis. Paper presented at: the 19th International Leksell Gamma Knife Society Meeting, Dubai; March 6, 2018; United Arab Emirates.


